Seres Therapeutics Inc. (MCRB:NASDAQ; 1S90:FSE), a clinical-stage company developing live biotherapeutics to modulate the gut microbiome for oncology and inflammatory conditions, released Q3 2026 financial results on November 4, 2026, highlighting plans to advance SER-155 for preventing immune checkpoint inhibitor-related enterocolitis (irEC) while facing a tight cash position that has weighed on the stock despite encouraging clinical data.
Key Investor Takeaways
- Seres is advancing SER-155 for irEC prevention following positive IST data showing an 80% immunosuppression-free response.
- Cash of US$17.5 million plus the October Nestlé SA (NESN:VX; NSRGY:OTC) payment funds operations only through Q1 2027, driving the need for partnerships.
- The irEC program targets a large population of ICI (immune checkpoint inhibitor) patients, estimated at 300,000 in the U.S., representing a potential multi-billion-dollar opportunity.
- Positive Phase 1b results for SER-155 in allo-HCT were published in Nature Medicine on November 3, 2026, with 77% relative risk reduction in bloodstream infections.
- Cost reductions, including workforce and facility adjustments, support the current runway but highlight execution risks tied to funding.
Q3 2026 Results and irEC Development Plans
The November 4 press release detailed a net loss of US$16.3 million for the quarter, compared to a net income of US$8.2 million a year earlier. The difference was primarily due to the absence of a US$25 million installment payment received in the third quarter of 2025 related to the sale of the VOWST business to Nestlé, which was recognized as a gain on sale. Research and development (R&D) expenses fell to US$5.6 million from US$12.6 million, reflecting cost reductions. Cash and equivalents stood at US$17.5 million as of September 30, 2026, with an additional US$12.5 million received from Nestlé in October, supporting operations through Q1 2027, excluding new capital.
Seres develops novel live biotherapeutics that target the mucosal epithelial barrier-immune interface in the gastrointestinal tract. Its lead candidate, SER-155, has received Breakthrough Therapy and Fast Track designations for preventing bloodstream infections in allogeneic hematopoietic cell transplant patients and is Phase 2 ready for that indication, pending funding, with a recent Nature Medicine publication on November 3, 2026, showing a 77% relative risk reduction in BSIs versus placebo.
The irEC prevention program aims to keep cancer patients on ICI therapy by reducing enterocolitis incidence, avoiding immunosuppressive treatments that can compromise anti-cancer effects. This builds on an investigator-sponsored trial at Memorial Sloan Kettering where 12 of 15 patients (80%) with moderate-to-severe irEC achieved an immunosuppressive-free clinical response at Day 15, with no drug-related serious adverse events. Seres plans to submit the study design to the FDA in Q1 2027. Earlier programs include SER-428 for sepsis patients and SER-603 for inflammatory bowel disease.
Despite the encouraging 80% response rate in the irEC IST and the Nature Medicine publication, Seres faces financial challenges, with its cash runway extending only through the first quarter of 2027 and additional funding needed to advance its clinical programs. The Q3 results underscored ongoing net losses and reduced expenses from prior restructuring, including a lease termination. Biotech investors often react to near-term funding needs and the absence of immediate revenue, even with clinical progress in high-unmet-need areas like oncology supportive care.
Gut Health in the Oncology Sector
The gut microbiome has become an area of increasing interest in oncology drug development, particularly as researchers investigate its influence on the effectiveness and tolerability of ICIs. An October 2026 review published in The Lancet Oncology described how intestinal microorganisms can influence cancer treatment outcomes through immune activation, antigen presentation, metabolic signaling, and intestinal barrier integrity.
The review also identified fecal microbiota transplantation, dietary interventions, and live biotherapeutic products as emerging approaches under clinical investigation, although these strategies remain experimental.
Matthew Keller, Ph.D., of H.C. Wainwright & Co. reiterated a "Buy" rating and US$12 price target on Seres.
One area of focus is immune-related colitis and enterocolitis, gastrointestinal complications associated with ICI treatment that can cause diarrhea, abdominal pain, and intestinal inflammation.
According to the American Society of Clinical Oncology (ASCO), published colitis incidence rates range from 8% to 27%, depending on the treatment regimen. For moderate-to-severe cases, corticosteroids are generally recommended as first-line treatment, with additional immunosuppressive therapies such as infliximab or vedolizumab considered when patients do not respond adequately.
Clinical research is beginning to evaluate several approaches, including fecal microbiota transplantation (FMT) and defined live bacterial therapeutics. A Phase 1 study published in Nature Medicine on January 28, 2026, evaluated donor-derived FMT alongside ICI-based treatment in 20 patients with metastatic renal cell carcinoma. The study primarily assessed safety, including the incidence and severity of immune-related adverse events.
Buy Ratings Despite Low Cash Flow
In a November 4, 2026, research note, Matthew Keller, Ph.D., of H.C. Wainwright & Co. reiterated a "Buy" rating and US$12 price target on Seres, emphasizing the potential of lead candidate SER-155. Keller's outlook centered around recent Phase 1 results, supporting the company's decision to investigate the drug as a preventive treatment in patients initiating immunotherapy.
While Seres' quarterly loss came in wider than Keller's estimate and its cash runway extends into Q1 2027, he maintained his rating and target, with his valuation primarily reflecting SER-155's potential across irEC and bloodstream infection prevention in transplant patients. He also sees potential partnering opportunities for the company's live biotherapeutic pipeline as a source of non-dilutive funding and support for further clinical development.
According to TipRanks, other recent analyst coverage includes a reiterated November 4 "Buy" rating and price target of US$22 from John Newman of Canaccord Genuity.
Ownership and Share Structure1
Management and insiders own approximately 56.00% of Seres Therapeutics, strategic entities hold about 11.76%, and institutions hold about 11.38%, with retail investors accounting for the balance.
The largest disclosed holder is Flagship Pioneering, LLC at about 11.76%.
The company has roughly 9.83 million shares outstanding and a market capitalization of about US$15.67 million.
Insiders were sellers over the last six months, selling about 964 shares, with no verified open-market purchases in that window.
One series of warrants remains outstanding. Public records show one historical share restructure.
Common Questions from Investors
What does Seres Therapeutics make?
Seres develops oral live biotherapeutics, including SER-155, designed to strengthen gut barrier function, reduce inflammation, and prevent pathogen overgrowth in oncology and inflammatory disease settings.
Why has the stock declined despite positive trial data?
Investor focus has centered on the company's US$17.5 million cash position and short runway, creating uncertainty around funding for Phase 2 and later studies even as clinical results for SER-155 remain encouraging.
What is the next catalyst for SER-155?
Seres expects to submit the irEC prevention study design to the FDA in the first quarter of 2027, with potential data readouts dependent on securing additional capital.
How does the irEC program compare to the allo-HCT indication?
Both leverage SER-155's mechanism; the allo-HCT program is Phase 2 ready with published positive data, while irEC prevention is earlier but targets a broader ICI-treated population.
| Want to be the first to know about interesting Biotechnology / Pharmaceuticals investment ideas? Sign up to receive the FREE Streetwise Reports' newsletter. | Subscribe |
Important Disclosures:
- Cori Fisher wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
- This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
- This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.
For additional disclosures, please click here.
1. Ownership and Share Structure Information
Ownership percentages, named holders, share count, market capitalization, and the 52-week range for Seres Therapeutics were compiled from company public filings and investor materials, exchange notices, insider-trade reports (SEDI / equivalent), and third-party data providers. Figures are as of 2026-11-11 unless a source was dated earlier. Pie slices are normalized to 100% of basic shares outstanding; retail is the residual after disclosed institutions, management, insiders, and strategic holders. Warrant terms are current outstanding series only. Restructures are historical consolidations, splits, and symbol or name changes. Insider buying and selling covers open-market trades from the prior six months through 2026-11-11 and excludes option exercises. These are public-source estimates and can differ from a later official register.
